PROUDLY PRESENTS

RegisteR byJune 3, 2011

foR eaRly biRd pRicing

Our EstEEmEd spEakEr FacultyBrent Bankosky, Senior Director, Global Licensing & Business Development, TAKEDAanthony Coyle, Vice President, and Chief Science Officer, Global Centers for Therapeutic Innovation, PFIZERtim Dolan, Director, Business Development, ELI LILLYlinDa egger, PhD, Senior Director, Scientific Liaison, External Scientific Affairs – Diabetes and Obesity Licensing, MERCKalan lamont, Director, SPBD, Science and Technology Licensing, ASTRAZENECAreiD leonarD, Executive Director, External Licensing and Scientific Affairs, MERCKDipanjan nag, PhD, Executive Director, Office of Technology Commercialization, RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYsriDaran natesan, Scientific Site Head, R&D, Head, External Innovation and Partnering, SANOFI-AVENTISlita nelsen, Director, Technology Licensing Office, MASSACHUSETTS INSTITUTE OF TECHNOLOGYCat oyler, Senior Director of Emerging Technologies, Corporate Office Science and Technology, JOHNSON AND JOHNSONalan palkowitz, PhD, Vice President of Discovery Chemistry Research and Technologies, ELI LILLYamy porter, Partner, THE ALLIANCE MANAGEMENT GROUP, Former Senior Director of Licensing, PFIZERChristian prothmann, Director, Alliance Management, NYCOMEDaaron sChaCht, Executive Director, Global R&D, ELI LILLYlen smith, Principal Intellectual Property Counsel, MEDICIS PHARMACEUTICAL CORPORATIONmorten sogaarD, Executive Director & Head Biotechnology, External R&D Innovation, Worldwide R&D, PFIZERjeff wasserstein, Senior Vice President Business Development and Strategy, NYCOMEDBryn williams-jones, eBiology Group Leader, PFIZER

Featuring Presentations From Leading universities and PharmaceuticaL comPanies:

Creating an eXternal portfolio Case stUDy

Sourcing, Developing, and Funding New Molecules ThroughOutside SourcesAaron Schacht, Executive Director, Global R&D, eLi LiLLY

partnering with aCaDemiC institUtions

How Pharmaceutical Companies can Benefit from and Contribute to the Expansive Research Being Done at Academic Institutions in the Form of Private-Public PartnershipsReid Leonard, Executive Director, External Licensing and Scientific Affairs, mercK

pre-CompetitiVe Case stUDy

The Open Pharmalogical Space ProjectBryn Williams-Jones, eBiology Group Leader, PFiZer

Pharmaceutical research collaborations summitEstablishing Value and Ensuring Successful Operations when Choosing to Collaborate with Strategic Partners, Public-Private Partnerships, Universities, and Open Innovation Programs

J u Ly 2 6 - 2 7, 2 0 1 1 – R A D I S S O n H O T E L B O S T O n – B O S T O n, M A

don’t miss the executive PaneL:COLLABORATIONS OVERVIEW PANEL: Leaders from Big Pharma, Academia, Smaller Biotechs, Non-Profits, and Government Discuss Collaborations Between Groups • Howeachstakeholdercanbenefitinacollaborativepharmaceutical research partnership• Evaluatingthepublichealthconcernsthatdriveprivate-publicpartnerships• Economicfactorsaffectinghowindustryandacademiaconduct biomedical research alan lamont, Director, SPBD, Science and Technology Licensing, ASTRAZENECA Brent Bankosky, Senior Director, Global Licensing & Business Development, TAKEDA

lita nelsen, Director, Technology Licensing Office, MASSACHUSETTS INSTITUTE OF TECHNOLOGY

tim Dolan, Director, Business Development, ELI LILLY

radissOn HOtEl BOstOn200 Stuart Street, Boston, MA 02116Tel: (617) 482-1800

SituatedinthecenteroftheexcitingBostonTheaterDistrictandjustoneblockfromBostonCommon, the Radisson offers guests a prime location in the heart of downtown Boston, MA. Hotelamenities includeaFitnessCenter,parkinggarage(feeapplies),BusinessCenter, tworestaurantsandanindoor,heatedpool.OnlythreemilesfromLoganAirport,FenwayPark,theChildren’s Museum and other popular attractions, the Radisson is one of the most convenient downtown Boston hotels for business and leisure travelers. RO O M R E S E RVAT I O NSIfyourequireovernightaccommodations,pleasecontacttheRadissonHotelBostonat(800)395-7046  tobookyourroom.ExLhasreservedablockofroomsatadiscountedrateforcon-ferenceparticipants.PleasementionExLPharmaandtheconferencenametotakeadvantageofthediscount.YoumustbookyourroombyMonday,July4,2011tobeeligibleforthedis-countedrate.Pleasebookyourroomearly,astheroomsavailableatthisratearelimited.

WHO sHOuld attEnd? From Pharma and Biotech companies, Managers, Directors, Vice Presidents of:• ClinicalResearch• BusinessDevelopment• ExternalRelations• Licensing• AllianceManagement• ScientificAffairs• Innovation• OpenInnovation• DrugDiscovery• ProjectManagement• ResearchProjects• R&D• StrategicAlliances• ClinicalPrograms• Strategy• M&A

yoU will also meet representatiVesfrom UniVersity offiCes of teChnology transfer anD CommerCialization

lEarn HOW tO Enlist tHE HElp OF:• Lawfirmsspecializinginintellectualproperty• Operatorsoflaboratories• Clinicalresearchorganizations• Openinnovationserviceproviders• Financialinstitutions

hotel information

Dear Colleague,I’m writing to introduce to you ExL Pharma’s Pharmaceutical Research Collaborations Summit.Pharmaceuticalcompanies,universities,andpublicagenciesallhaveastakeinadvancingthemedi-cal research that will lead to the pharmaceutical remedies of tomorrow. Research and development ismoreimportantthanever,andwithfewerresearchersandleanerbudgets,scientistsarelookingoutside of their home organizations to other sources of brainpower and funding.

Exl’s Pharmaceutical Research Collaborations Summit brings together the Clinical Research and BusinessDevelopmentDirectorswhohaveforgedsuccessfulworkingpartnerships.Theseinnovatorshave combined the expertise of multiple teams, creating synergy between often divergent research methodologies and goals. Hear as scientists from big pharma, biotech startups, universities, govern-ment agencies, and private research foundations discuss how they found each other and overcame structural differences to continue to provide patients of tomorrow with the medicines they need.

Let’sworktogethertoreapthebenefitsofworkingtogether.Ilookforwardtoseeingyouin July!

Sincerely,

Dave HoffmanConference Directordhoffman@exlpharma.com

spOnsOrsHip and ExHiBiting OppOrtunitiEs:Doyouwanttospreadthewordaboutyourorganization’ssolutionsandservicestopotentialclientswhowillbeattendingthisevent?Takeadvantageoftheopportunitytosponsor,underwriteaneducationalsession,hostanetworkingevent,ordistributepromotionalitemstoattendees.ExLPharmawillworkcloselywithyoutocustomizeapackagethatsuitsallyourneeds.To learnmoreabouttheseopportunities,pleasecontactEricMorrin(212)400-6228,oremorrin@exlpharma.com.

conFerence daY one, TueSdAy, July 26, 2011P R E - C O N F E R E NC E WO R K S H O P

9:00 translating Contractual expectations into the research process to avoid the results of irreconcilable Violations

• Involvinglawyersafteraprojecthasstartedcanbringdisastrousdelays• Ensuringacademicresearchersunderstandthattheymayhavetodelaypublicationoftheirresults–possiblynullifyingintellectual property – even though publication is often their ultimate goal• Determiningwhattodowithincidentaldiscoveriesaheadoftime• Anticipatingthepotentialofbeingapproachedtoenterintoconflictingagreementswithotherpartnerswhilemaintaining pre-determinedconfidentialityandownershipobligations• Makingsuretheobviousgetsdone

Amy Porter, Partner, THE ALLIANCE MANAGEMENT GROUP, Former Senior Director of Licensing, PFIZER

10:30 NetworkiNg aNd refreshmeNt Break

11:00 workshoP resUmes

12:00 workshoP CoNClUdes; lUNCh for workshoP atteNdees

1:00 welCome anD Chairperson’s introDUCtionMorten Sogaard, Executive Director & Head Biotechnology, External R&D Innovation, Worldwide R&D, PFIZER

COLLABORATIONS OVERVIEW PANEL1:15 leaders from Big pharma, academia, smaller Biotechs, non-profits, and government Discuss Collaborations Between groups

• Howeachstakeholdercanbenefitinacollaborativepharmaceutical research partnership• Whatbarriersexistintermsofpromotingbetterpharma:academia collaborations, and what are both parties are doing to address these?• Evaluatingthepublichealthconcernsthatdriveprivate-public partnerships• Economicfactorsaffectinghowindustryandacademiaconduct biomedical research

Alan Lamont, Director, SPBD, Science and Technology Licensing, ASTRAZEnECALita nelsen, Director, Technology Licensing Office, MASSACHuSETTS InSTITuTE OF TECHnOLOGyBrentBankosky,Senior Director, Global Licensing & Business Development, TAKEDATim Dolan, Director, Business Development, ELI LILLy

ASSESSING THE COLLABORATIVE LANDSCAPE2:00 seeking innovation internally and externally at merck

• Thebenefitsofpre-competitivecollaborationsforveryearlyresearch andbiomarkerdiscoverywhereanyonecanbenefit• Partneringwithacademicinstitutionswhomaynothavethe capability to move beyond early research• Workingwithbiotechcompanieswithlowupfrontcommitmentina risk-sharing/optionagreementtobringpartnershiptothenextlevel• Determiningtherightdealstructureforlaterstageresearchwhen acquisitions may become desirable

Linda Egger, PhD, CLP, Senior Director, Scientific Liaison, External Scientific Affairs – Diabetes and Obesity Licensing, MERCK

2:45 NetworkiNg aNd refreshmeNt Break

PROVIDING STRATEGIC GRANTS3:15 Bridge the funding gap at early stages of the partnering spectrum

• Novelapproachesforaccessingearlyresearchdiscoveries• Maximizingcollaborationandresearchimpact• Bridgingthenextsteps:howtotranslateastrategicgrantintoa strategic fit• Determiningwhereandhowtheprojectmightfitwiththecompany after the independent funding stage in a way that benefits both partners

Cat Oyler, Senior Director of Emerging Technologies, Corporate Office Science and Technology, JOHnSOn AnD JOHnSOn

CREATING AN EXTERNAL PORTFOLIO CASE STUDY4:00 sourcing, Developing, and funding new molecules through outside sources

• Supportingthebusinessdevelopmentdealflowthroughtraditional surveillance activities• Helpingexternalmoleculedevelopersputtogetherproofofconcept packageswiththeChorusGroup• RaisingventurefundstoexpandLilly’scapabilitytodevelop

Aaron Schacht, Executive Director, Global R&D, ELI LILLy

CASE STUDY ON PFIZER’S GLOBAL CENTERS FOR THERAPEUTIC INNOVATION4:45 partnering with the University of California san francisco to engage external scientists as a key Component of an r&D strategy

• Openinnovationasacomplimenttopartneringwithbiotechstartups for drug discovery• Determiningincentivizingintellectualproperty,ownership,and publication rights to support continued experimentation and exploration by external scientience• HowafluidopeninnovationprogramhashelpedexpandPfizer’s pipeline with new, highly differentiated candidate drugs

Anthony Coyle, Vice President, and Chief Science Officer, Global Centers for Therapeutic Innovation, PFIZER

5:30 eNd of day oNe

conFerence daY two, WedneSdAy, July 27, 2011

9:00 Chairperson’s recap of Day oneMorten Sogaard, Executive Director & Head Biotechnology, External R&D Innovation, Worldwide R&D, PFIZER

PANEL DISCUSSION: ALLIANCE MANAGEMENT AS A BUSINESS ART9:15 the increasingly important role of alliance management as Collaborative research partnerships grow in importance

• ImprovingtheoutputofearlyR&Deffortsbycombiningefforts• Identifyingandimplementingalliancemanagementbestpracticesin all collaborations• Trainingtheprojectandproductmanagers

MODERATOR: Amy Porter, Partner, THE ALLIANCE MANAGEMENT GROUP, Former Senior Director of Licensing, PFIZERPANELISTS: Christian Prothmann, Director, Alliance Management, NYCOMED

PRE-COMPETITIVE CASE STUDY10:00 the open pharmalogical space project

• Facilitatingtheprocessofextractingvaluefrompublicdata• SavingR&DmoneyforbiomedicalresearchbysharingIT infrastructure of organizing data for early research

BrynWilliams-Jones,eBiology Group Leader, PFIZER

10:45 NetworkiNg aNd refreshmeNt Break

PARTNERING WITH ACADEMIC INSTITUTIONS11:15 how pharmaceutical Companies can Benefit from and Contribute to the expansive research Being Done at academic institutions in the form of private-public partnerships

• Determininghowacademicresearchmaycontributetocommercial projects to justify funding• Meldingexistingacademicresearchwithpublichealthneedsto determine commercial viability to justify funding• WhatkindofIPagreementsaremostappropriateforpublic-private partnerships• Successfullymatchingcorporateresearchgoalsanddeadlineswith academic goals and deadlines

Reid Leonard, Executive Director, External Licensing and Scientific Affairs, MERCK

RECONCILING DIFFERENT EXPECTATIONS12:00 anticipating Conflicts when working with academic researchers on Commercial projects

• Whataretheimportanttouchpointstoconsiderwhenenteringinto a research partnership between an academic institution and a pharmaceutical company• Understandingwhatmakesuniversitiestickandbigpharmatick• Whathappenswhenscientistsareexpectingtopublishtheir universityworkthatisfundedaspartofapharmaceuticalcompany’s pipeline?Whataboutrelatedworkthatpredatesthecurrentproject?• Makingsureyourinitialcontractaccountsforcorollarydiscoveries, any other existing or future partnerships, and other expectations

Dipanjan nag, PhD, Executive Director, Office of Technology Commercialization, RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY

12:45 lUNCheoN

OPEN INNOVATION CASE STUDY: THE LILLY PHENOTYPIC DRUG DISCOVERY INITIATIVE

1:45 working with research Universities, institutes, and Biotech to Uncover Compounds that may Become future medicines• Providinginvestigatorsphenotypicassaypanelsatnocost• Usingaweb-basedinterfacetofacilitateconfidentialcompound submission• Usingpromisingfindingsasthebasisforacollaboration agreement

AlanPalkowitz,PhD,Vice President of Discovery Chemistry Research and Technologies, ELI LILLY

IDENTIFYING PRODUCT OPPORTUNITIES2:30 matching your internal pipeline needs with research Being Done outside your Company

• UsingIPtoensureabroaderscientificsupportbasetoreducerisk• Takingadvantageofexternalsourcesforpiecesofthepuzzlethatwill build up the product profile • Decidingwhenitisbesttoworkwithbiotechs,universities, hospitals,orpre-competitivecooperativegroups• Assessingthemarketvalueofanypartnershipbasedonyour development pipeline

Jeff Wasserstein, Senior Vice President Business Development and Strategy, NYCOMED

3:15 NetworkiNg aNd refreshmeNt Break

ALLIANCE PROJECT MANAGEMENT PANEL3:45 accounting for Differences in expectations and structure when managing researchers from Different teams

• Integratingandmanagingtwoteamsfromdifferentorganizational structures(i.e.universityandbigpharma)whomayhavedifferent process and goal expectations - Establishingagreementandmutualunderstandingofdeadlines - Instatingaprojectmanagementstructurethatwillworkforboth partners• Includingotherdepartmentsoutsidetheresearchteaminthe research - Marketing• MakingsuretheIPagreementsareinplacebeforediscoveriesbegin to happen

Sridaran natesan, Scientific Site Head, R&D, Head, External Innovation and Partnering, SANOFI-AVENTIS

IP AGREEMENTS4:30 Contracting Between pharmaceutical Companies and outside research Collaborators for maximum mutual Benefit

• Aligningthegoalsofbothpartiestofacilitateacongruentresearch process• HowdifferentIPagreementsmaybemoreorlessappropriatefor different phases of research - Discovery - ClinicalPhases• HowmuchcanyourcompanystandardizeIPagreements–especially in cases of broader open innovation initiatives

Len Smith, Principal Intellectual Property Counsel, MEDICIS PHARMACEUTICAL CORPORATION

5:15 eNd of CoNfereNCe

make checks payable to exl events, inc. and write code p912 on your check.YoumayalsouseVisa,MasterCard,DiscoverorAmericanExpress.Paymentsmustbereceivedinfullpriortothecommencementoftheconference.Cancellations: IfyouneedtocancelyourregistrationforanupcomingExLconference,pleasenotethefol-lowingpoliciesderivedfromtheStartDateoftheevent:four weeks or more:Afullrefund(minusa$95processingfee),oravouchertoanotherExLeventvalidfortwoyearsfromthevoucherissuedate.four weeks or less:AvouchertoanotherExLeventvalidfortwoyearsfromthevoucherissuedate.Toreceivearefundorvoucher,pleasefaxyourrequestto888-221-6750.please note: Conference registrations may be transferred to other colleagues in the event you are unable to attend. Therewillbeanadministrativechargeof$300tosubstitute,exchangeand/orreplaceattendancebadgeswithacolleagueoccurringwithinfivebusinessdaysofanyExLconference.PleasenotifyExLPharma,info@exlpharma.com,priortotheeventwiththenameandcontactinformationofthereplacementattendee.please note: Speakersandagendaaresubjecttochangewithoutnotice.Intheeventofaspeakercancella-tion,everyefforttofindasuitablereplacementwillbemade.

*The opinions of this faculty do not necessarily reflect those of the companies they represent or ExL Events, Inc.*

F VE Ways tO rEgistEr

registration Fees for attending Exl pharma’s pharmaceutical research collaborations summit:

early Bird PricingRegister by Friday, June 3, 2011 to Take Advantage of Early-Bird Pricing:C o r p o r at e r at e sConference+Workshop $1995Conference Only $1695a C a D e m i C , n o n - p r o f i t, g o V e r n m e n t r at e s *Main Conference Only $995MainConference,plusWorkshop $1195

standard PricingRegister After Friday, June 3, 2011: C o r p o r at e r at e sConference+Workshop $2195Conference Only $1895a C a D e m i C , n o n - p r o f i t, g o V e r n m e n t r at e s *Main Conference Only $1195MainConference,plusWorkshop $1395

Workshop $1495

* Mustbeemployedfull-timebyapharmaceutical,biotechnology,and/ormedicaldevicecompanyto qualifyforthisrate.Ifyouregisterincorrectlyatthewrongrate,youwillbechargeda$95processingfee tocanceltheregistration.Ifyouhaveanyquestionsaboutyoureligibilityforthisrate,pleasecontactDave Hoffmanat(917)258-5144,dhoffman@exlpharma.com

grOup discOunt prOgram: save 25% per person when registering four Foreverythreesimultaneousregistrationsfromyourcompany,youwillreceiveafourthcomplimentaryregistrationtotheprogram(mustregister4atonetime).Thisisasavingsof25%perperson.

save 15% per person when registering three Canonlysendthree?Youcanstillsave15%offofeveryregistration.Tofindoutmoreonhowyoucantakeadvantageofthesegroupdiscounts,pleasecall866-207-6528.

media partners

Exp. Date:

Name on Card

Signature

T O R E G I S T E R

Yes! Register me for the Conference and Workshop:

Register me for the conference only

Please contact me: I’m interested in marketing opportunities at this event

I wish to receive email updates on ExL Pharma’s upcoming events

Name Title

Company

Dept.

Address

City State Zip

Email

Telephone

s at www.exlpharma.com/collaborationssummit

Card Number

Name r

Signature r